- Money Masters
- Posts
- 4 Best Blue-Chip Buys
4 Best Blue-Chip Buys
Kenny
December 27, 2024
In partnership with
2 Cards Charging 0% Interest Until 2026
Paying down your credit card balance can be tough with the majority of your payment going to interest. Avoid interest charges for up to 18 months with these cards.
THE MONEY IDEA💡
4 Best Blue-Chip Buys
Welcome to Money Masters!
Investors seeking stability and long-term growth often turn to blue-chip stocks, as they tend to possess strong financials and proven track records. In this article, we highlight the 4 Blue-Chip Buys mentioned by Morningstar experts, each offering a unique mix of value, resilience, and growth potential. These stocks are currently trading below fair value, making them compelling opportunities for savvy investors looking to build a solid portfolio foundation.
Let’s dive in.
THE MONEY IDEA💡
4 Best Blue-Chip Buys
Undervalued Opportunity: Trading 42% below Morningstar's fair value estimate of $90 per share.
Global Leadership: Vast scale and regional dominance through acquisitions like Grupo Modelo and SABMiller.
Cost Efficiency: Among the most efficient operators with strong cost advantages in the consumer defensive sector.
Cash Flow Strength: Consistently high free cash flow conversion compared to industry peers.
Future Potential: A focus on reducing debt to minimize earnings volatility further enhances growth prospects.
Market Dominance: The largest athletic footwear brand globally, excelling in categories like running and basketball.
Innovation-Led Growth: Triple Double strategy focuses on doubling innovation, speed, and direct consumer engagement.
Emerging Market Potential: Opportunities for revenue growth in China and other international markets.
Resilient Brand: Overcoming challenges like uneven demand and local competition with a strong brand legacy.
Undervalued Opportunity: Trades at a 34% discount to fair value, with potential upside to $117 per share.
Diverse Portfolio: Home to globally recognized brands like Nescafe, Perrier, and Purina.
Growth Revitalization: Active portfolio management targets high-growth categories such as pet care and nutrition.
Cost Efficiency: Structural improvements and cost-cutting measures enhance profitability.
Stable Yield: Offers a reliable 3.96% dividend yield for income-focused investors.
Long-Term Potential: Trades at a 29% discount to Morningstar’s fair value estimate of $116 per share.
Premier Supplier: Dominates the life sciences industry with an unmatched product portfolio.
Global Resilience: Strong customer relationships and manufacturing capabilities amid economic challenges.
Long-Term Growth: Positioned to capitalize on increasing biopharma demand as budgets recover.
Market Leadership: A leader in diagnostics and research, with consistent performance.
Discounted Valuation: Trades at a 16% discount to fair value, with a target of $630 per share.
The Content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
We are excited about our own crypto:
CRYPTO CORNER📈
Margentum
Join the revolution with Margentum, the digital silver designed to complement Bitcoin’s digital gold. Within the first 24 hours, our market cap surged from $7,000 to $19,000, with ambitious plans to reach the billions and beyond. Built on the powerful Solana blockchain, Margentum offers stability, speed, and unmatched scalability.
Be part of this groundbreaking journey. Learn more at Margentum.com and discover how Margentum is shaping the future of digital value.
NEWSLETTER CORNER🗞️
Subscribe To Our Friends!
QUOTE CORNER📄
Quote of The Week
You are now closer to money mastery!🎉
What did you think of this week’s newsletter?
Did you like it? How can we improve?
Hit reply and share some feedback!
Reply